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Abstract
Specialized phagocytes are found in the most primitive multicellular organisms. Their roles in
homeostasis and in distinguishing self from non-self have evolved with the complexity of
organisms and their immune systems. Equally important, but often overlooked, are the roles of
macrophages in tissue development. As discussed in this Review, these include functions in
branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the
generation of adipose tissue. In each case, macrophage depletion impairs the formation of the
tissue and compromises its function. I argue that in several diseases, the unrestrained acquisition
of these developmental macrophage functions exacerbates pathology. For example, macrophages
enhance tumour progression and metastasis by affecting tumour-cell migration and invasion, as
well as angiogenesis.
A century after Metchnikoff's Nobel Prize for the discovery of macrophages and innate
immunity, it is being increasingly appreciated that macrophages have many non-
immunological trophic roles during development. In fact, Metchnikoff1 originally regarded
the motile phagocytic cells that he first observed in Ascidians as homeostatic regulators that
were involved in maintaining the integrity of an organism through a process he called
`physiological inflammation'. He contrasted this term with `pathological inflammation'
resulting from external challenges, which we now know as innate immunity1. In this
Review, I discuss evidence indicating that the most ancient and still extremely important
roles of macrophages relate to developmental processes. Furthermore, I illustrate how
pathogenic processes such as cancer can subvert these developmental functions of
macrophages, resulting in potentiation of disease.
Macrophage origin and classification
Macrophage lineages
The definition of a macrophage has challenged developmental biologists since these cells
were first described. Originally, the emphasis was on phagocytosis, which led to the term
macrophages (from the Greek for large eaters) to distinguish these cells from the
polymorphonuclear microphages (from the Greek for small eaters; neutrophils). This study
of phagocytosis identified two types of macrophage cell: cells that aligned the endothelium
and amoeboid cells known as histiocytes2,3. This definition evolved into the
reticuloendothelial system (RES) of classification, which suggested that these two types of
cell had a common origin as they both cleared particles from the blood. However, as many
cells can be phagocytic and because endothelial cells and histiocytes are morphologically
and functionally distinct, the use of the RES to classify macrophages went out of favour and
was replaced by a system that classified macrophages based on ontogeny and phagocytosis,
which was named the mononuclear phagocytic system (MPS)3. It included bone-marrow-
derived precursor cells, monocytes in the peripheral blood and mature macrophages in
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tissues, but excluded endothelial cells and other mesenchymal cells that are not obviously
derived from the bone marrow. More recently, the classification of the MPS has been
refined, as it has become clear that some dendritic cells (DCs) can differentiate from
monocytes and macrophages4,5. The MPS has been prominent for the past four decades, but
the recent identification of myeloid precursor cells that differentiate into endothelial cells6
indicates that a re-examination of the RES might be required7.
The MPS is largely an ontological definition for vertebrates and it is useful for classifying
macrophages in adults. However, the origin of these phagocytic cells in embryos is more
complex. In mice, the first population of macrophages is observed at the late head-fold stage
(embryonic day (e)7.5) and is of maternal origin8. Embryonic macrophages (derived from
the primitive endoderm of the yolk sac) are first found around e8 and invade the anterior
structures of the embryo. These cells do not go through a monocytic stage but differentiate
directly from mesenchymal progenitor cells7. Haematopoietic progenitor cells from the yolk
sac of rats and mice first populate the primitive liver, which is the first site of definitive
haematopoiesis, and at e10 are followed by a second wave of progenitor cells from the
aorta–gonads–mesonephros region of the embryo9–11. By e10.5 to e11, the primitive liver is
the main site of haematopoiesis and thereafter macrophages that have differentiated from
monocytic progenitor cells are found throughout the embryo10,11. After birth, the bony
structures are formed and as a result the main site of haematopoiesis is the bone marrow; at
this stage, the MPS is established3 (FIG. 1).
In mammals, macrophages are found in all tissues after birth (TABLE 1). In some tissues,
they constitute 10–20% of all cells — for example, microglial cells in the brain and Kupffer
cells in the liver — whereas in other tissues, such as at the musculo–skeletal junctions, they
are rare12,13. In addition, monocyte- or macrophage-derived DCs (FIG. 1) are often found in
precise locations and are given distinct names; for example, Langerhans cells in the
skin13–15.
During development, the density of macrophages changes in many tissues14. The expression
of green fluorescent protein (GFP) by the mononuclear phagocytic lineage under the control
of the Csf1r (colony-stimulating factor 1 receptor) promoter13,16 has shown striking,
organized patterns of macrophages in tissues. However, a caveat of these studies is that the
transgenic reporter also marks neutrophils, although these are rare in most tissues and are
also easily distinguished because of their polymorphonuclear morphology. using a truncated
Csf1r promoter, the expression of which is more restricted to macrophages, similar patterns
of macrophage tissue expression have been observed, which are consistent with F4/80-
specific antibody staining for macro phages14,16,17. These analyses also show that there are
marked morphological differences within and between macrophage populations, ranging
from highly dendritic to round morphologies.
Macrophage classification
The diversity of macrophage functions has led to various classification attempts. Given the
immune functions of macrophages, the first type to be described was the `classically
activated' macrophage that responds to interferon-γ (IFNγ) by releasing pro-inflammatory
cytokines, such as interleukin-12 (IL-12) and IL-23, and that is involved in the T helper 1
(TH1)-cell-mediated immune resolution of infection18. In contrast to this are the
`alternatively activated' macrophages, which respond to TH2-type cytokines, such as IL-4
and IL-13, and are involved in fibrosis, tissue repair and humoral immunity19. These two
opposite phenotypes have been designated by some as M1- and M2-type macrophages19.
There was also an appreciation that some macrophages are involved in wound repair, and
these cells were thought to be a subpopulation of M2-type macrophages20. In addition,
macrophages that are associated with tumours have been proposed to be M2-type
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macrophages19, emphasizing the tissue trophic and repair functions of macrophages.
However, I believe that the M1–M2 classification is overly restrictive. It ignores the
different fates of macrophages that develop in response to CSF1 (also known as M-CSF)
compared with those that develop in response to granulocyte/macrophage CSF (GM-CSF;
also known as CSF2). The differential development of these macrophages gives rise to cells
that are at opposite ends of the spectrum, with GM-CSF-regulated macrophages having
mainly immunological roles and CSF1-regulated macrophages having trophic roles21.
Another more flexible classification has been suggested recently in which macrophages are
part of a continuum and have a range of overlapping functions, with classically activated,
wound-healing and regulatory macrophages occupying different points of the spectrum22.
However, the developmentally important macrophages that are described in this and other
reviews9 have not been specifically included in any of these classifications. They form
another subpopulation that is grouped together with embryonic9 and wound-healing22
macrophages and with irreversibly differentiated osteoclasts. Each of these many different
types of macrophage is specified by the microenvironment, although there is considerable
plasticity between distinct types. This concept recalls Metchnikoff's original classification,
which considered macrophages as part of a continuum, keeping the self whole in
development and adulthood (physiological inflammation) and differentiating it from non-
self and the environment (pathological inflammation).
Factors involved in macrophage differentiation
The development of macrophages from monocytes is regulated by several growth factors. In
mice and rats at least, the most important of these is CSF1, which stimulates the
differentiation of macrophages from progenitors as well as their proliferation and viability in
vitro. CSF1R is expressed by all cells that are part of the MPS and helps to define them23.
But macrophages can also be grown and differentiated in vitro from monocytic progenitors
in the presence of GM-CSF and to a lesser extent in the presence of IL-3, which generates
immature macrophages, or IL-3 in combination with CSF1, which generates mature
macrophages21,24. In addition, the transcription factor PU.1, which among other functions
controls the expression of CSF1R, regulates differentiation of progenitors to the macrophage
lineage although its functions are not limited to cells that are part of the MPS.
Null mutations of the genes encoding all these factors have been generated or identified in
mice. In the absence of environmental or immunological challenge, the phenotype is mild
for both GM-CSF and IL-3 deficiency, with little effect on myeloid-cell density or function
except for cells that reside in the lung25–27. By contrast, Pu.1-deficient mice have a
depletion of B cells and granulocytes and also a significant decrease in the size of many
macrophage populations; these mice die perinatally28–30. During embryogenesis, the
development of macrophages from Pu.1-deficient mice is normal until they begin to
progress through the monocyte precursor stage10. A Pu.1-related transcription factor, Spic,
is also required for the development of population of splenic red pulp macrophages that
removes red blood cells31.
Mice with the naturally occurring null mutation in the Csf1 gene, known as osteopetrotic
(Csf1op)32, and mice that have a targeted null mutation in Csf1r are both severely depleted
of most macrophage populations. However, some macrophage populations such as those that
reside in the spleen are mostly unaffected, and there is little effect on other haematopoietic
lineages in these mice32. All of the phenotypes found in Csf1op/op mice are also found in
Csf1r−/− mice, which indicates that CSF1R is the only receptor for CSF1 (REF. 33).
However, several phenotypes are more severe in Csf1r−/− mice, and these mice rarely live
beyond a few weeks of age. More severe phenotypes of Csf1r−/− mice include the complete
loss of epidermal langerhans cells15 and microglial cells (B. Erblich and J.W.P., unpublished
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observations). By contrast, the numbers and physiology of these cells are relatively normal
in Csf1op/op mice14,34. Recently, another ligand, IL-34, has been identified that binds with
greater affinity to CSF1R than does CSF1, which can support myeloid-cell development in
vitro35. The biological functions of IL-34 remain to be determined but might explain the
differences between the phenotypes of Csf1op/op and Csf1r−/− mice. The specific
macrophage deficiencies observed in Csf1op/op mice confirm the important role of CSF1 in
regulating macrophage survival, proliferation and differentiation. Furthermore, Csf1op/op
mice on a mixed genetic background are viable, which has allowed for the analysis of the
function of their macrophages. Strikingly, Csf1op/op mice have few immunological
deficiencies except against pathogens that replicate in macrophages, such as Listeria
monocytogenes and mycobacteria, to which the mice were more susceptible36,37. However,
Csf1op/op mice have many developmental abnormalities that are attributable to the lack of
individual macrophage populations32. These data show that an important activity of
macrophages is their trophic functions during development, a topic that I discuss in the rest
of this Review32.
Trophic functions of macrophages
Bone morphogenesis
The most obvious phenotype of Csf1op/op mice is osteopetrosis, which is the result of the
depletion of osteoclasts (FIG. 2). Osteopetrosis is also observed in Csf1−/− rats (known as
toothless rats; tl rats) and in Pu.1-deficient mice32,38,39. Studies using Csf1op/op mice have
shown that CSF1 is essential for the development of a common monocyte–osteoclast bone
marrow progenitor cell that differentiates in response to receptor activator of nuclear factor-
κB ligand (RANKl; also known as TNFSF11) to become a multi-nucleated functional
osteoclast40 (FIG. 2). CSF1 also increases mature osteoclastic bone resorption41. Without
functioning osteoclasts, the bone is not re-sculpted and removed at the growth plate and
osteopetrosis ensues. Osteopetrosis causes a lack of a marrow cavity and consequently the
elimination of much of the haematopoiesis that normally occurs in the bone marrow,
although compensatory haematopoiesis still occurs in the liver and spleen42. It also results in
a lack of teeth because the tooth buds, although formed, cannot erupt through the jaw32,39.
In both Csf1op/op mice and tl rats, osteopetrosis and dental defects can be reversed by the
systemic administration of CSF1 (REFs 43,44). This osteopetrotic phenotype is one of the
best examples of the developmental requirement for a specialized type of macrophage and is
iconic of the tissue-trophic role of macrophages, the malfunction of which results in tissue
malformation and downstream physiological effects on haematopoiesis and tooth eruption.
Ductal branching
Many tissues are formed by the outgrowth of epithelial rudiments into an underlying
mesenchyme, which specifies their identity. A well-studied example is the mammary gland:
in mice that are at the beginning of puberty, the rudimentary mammary ducts develop
multilaminate bulbous termini known as terminal end buds (TEBs) that grow out through the
fat pad. While they do so, the mammary ducts divide to give rise to the branched ductal
structures of the mature mammary gland. Similarly, during pregnancy there is further ductal
outgrowth and extensive proliferation of the lobuloalveolar structures that produce milk
during lactation. As soon as the TEBs begin to grow during puberty, macrophages are
recruited and align along the TEB shaft45. In vivo imaging shows that these macrophages
move rapidly around the shaft of the TEB and cross over at the invading front46. These
movements are promoted by a collagenous cluster of fibres, mainly of collagen I, that run
parallel to the direction of the TEB outgrowth46. In addition, macrophages are found within
the TEB structure, where they phagocytose the apoptotic epithelial cells as the lumen is
formed45 (FIG. 3). Studies in Csf1op/op mice showed that macrophages were not recruited to
Pollard Page 4
Nat Rev Immunol. Author manuscript; available in PMC 2013 May 09.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the TEB and the rate of outgrowth of these ductal structures and their branching was
decreased45,47, resulting in an atrophic mammary gland. A similar defect was observed
during the ductal outgrowth that occurs during pregnancy, although lobuloalveolar
development was unaffected47. Importantly, the restricted transgenic expression of CSF1 in
cells in the mammary epithelium resulted in the recruitment of macro phages, which are the
only cells that express CSF1R, and the rescue of the branching defect, without correction of
the other systemic defects observed in Csf1op/op mice48. This study showed that the defect
was organ autonomous and macrophage specific. Although the mechanism behind these
macrophage activities remains to be fully elucidated, the formation of collagen fibrils but
not collagen I synthesis was inhibited in the Csf1op/op mice. Rescue of the macrophage
deficiency resulted in the formation of normal fibrils and the restoration of ductal outgrowth
and branching, which indicates that one function of macrophages is in matrix remodelling46
(FIG. 3).
Another example of the role of macrophages in ductal development also comes from studies
in Csf1op/op mice. Similarly to the mammary gland, macrophages are recruited adjacent to
the epithelial tissue as pancreatic islets form. Their absence in Csf1op/op mice results in
decreased mass of insulin-producing β-cells, abnormal post-natal islet morphogenesis and
impaired pancreatic cell proliferation49. A similar phenomenon is found during the
expansion of the pancreas in pregnancy49. In fact, macrophages are required throughout life
for the development and remodelling of the pancreas49. Furthermore, the addition of CSF1
stimulated an increase in the number of insulin-producing cells in pancreas explant cultures,
which was accompanied by an increase in the number of macrophages50. The effects of
macrophages on branching morphogenesis probably apply to other tissues as well. Indeed
macrophages are recruited to the developing kidney and to kidney explant cultures treated
with CSF1 in the presence of low levels of lipopolysaccharide, and this results in a
significant increase in the numbers of branch tips and nephrons9.
Neural networking
Csf1op/op mice have considerable reproductive defects51. Male mice have low libido and
sperm counts, which are attributable to low testosterone levels52, and female mice have poor
ovulation rates and extended oestrous cycles53. At first glance, these data are consistent with
the role of macrophages in the development and maintenance of gonadal tissue, as defined
by ablation studies. For example, in male mice, macrophages associate closely with the
testosterone-producing leydig cells in the testis, and their ablation using liposome-
encapsulated clodronate suppressed testosterone synthesis54. In female mice, macrophages
are recruited to the interstitium of the developing ovarian follicle, with maximum numbers
being present just before ovulation53, and a similar chemical ablation of macrophages
affects steroidogenesis and inhibits ovulation55,56. In Csf1op/op mice, macrophage density is
markedly decreased in gonadal tissues, interstitial structure is affected in the testes and the
morphology of Leydig cells is distorted52,57. Nevertheless, the primary defect in the
reproductive function of Csf1op/op mice occurs in the regulation of the hypothalamic–
pituitary–gonadal axis. In male Csf1op/op mice, the level of circulating luteinizing hormone,
which is the pituitary hormone that controls testosterone biosynthesis, is low and the
negative feedback mediated by sex steroid hormones such as testosterone, which regulates
the production of luteinizing hormone, is attenuated and inverted. As a result, the normal
increase in luteinizing hormone that is associated with testosterone removal does not occur,
and testosterone administration increases luteinizing hormone levels under conditions that
would normally decrease them57. Furthermore, administration of a gonadotrophin-releasing
hormone (GnRH) agonist that substitutes for endogenous GnRH production by the
hypothalamus rescues the luteinizing hormone deficiency in Csf1op/op mice (which shows
that the defect is at the level of the hypothalamus), and administration of luteinizing
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hormone restores testosterone levels57. In female Csf1op/op mice, there is also decreased
negative feedback on the hypothalamic–pituitary–gonadal axis following oestrogen removal
and a complete absence of the positive feedback to oestrogen that causes the surge in
luteinizing hormone, which is required for ovulation. In addition, a delay in puberty has also
been observed in these mice34.
Reconstitution of neonatal Csf1op/op mice with human recombinant CSF1 throughout their
lifetime rescued these hypothalamic deficiencies, restoring both feedback control and the
timing of puberty, and timed administration of CSF1 during the first 2 weeks of life almost
entirely reversed the defects34. These data show that the reproductive defects are primarily,
if not entirely, at the level of the hypothalamus or higher in the brain51 and that the absence
of CSF1 signalling during the crucial period of development when the hypothalamus is
sexualized results in a permanent impairment throughout life.
Evidence for neuronal defects in the brains of Csf1op/op mice has also come from studies
assessing auditory or visual evoked potentials (VEPs) that showed that the mice have
impaired auditory and visual processing58. Intracortical recordings of VEPs and multiple
unit activities (a summation of action potentials during stimulation) were attenuated and
persistent in the Csf1op/op mice compared with wild-type mice. By contrast, the time for
retinal striate conductance was the same, indicating that the CSF1 deficiency does not block
neuronal transmission. Furthermore, administration of a γ-aminobutyric acid A (GABAA)
antagonist (which overrides inhibitory signals) into the intracortical region of the brain in
Csflop/op mice resulted in attenuated but persistent firing, whereas in wild-type mice there
was a robust excitatory response with subsequent inhibition58. These data show a primary
neuronal deficit in Csf1op/op mice involving both excitatory and inhibitory signals (FIG. 4).
The brain is populated by a large number of macrophages, known as microglial cells, which
account for ~15% of the brain's cellularity. These cells express CSF1R in the brain during
development and in adulthood13,59, and indeed seem to be the only cells that express CSF1R
in the brain. They are therefore the only target cells of CSF1, which is also expressed in the
brain throughout life in spatially and developmentally specific ways58. Nevertheless, the
numbers of microglial cells in mice that are on a mixed genetic background are not
decreased in the Csf1op/op mice (although their signalling in response to CSF1 is non-
existent), despite a small developmental delay in their acquisition, and the brains of these
mice have an overall normal morphology34,60. By contrast, there is a complete absence of
microglial cells in Csf1r−/− mice (B. Erblich and J.W.P., unpublished observations) from
birth and at all stages of post-natal development. This is associated with marked structural
defects in the brain, including swollen ventricles, thinned cortex and decreased size of
olfactory bulbs. The contrast in the severity of phenotype between the receptor- and ligand-
deficient mice is particularly striking, and IL-34, acting as an alternative ligand for CSF1R,
might account for this discrepancy in the brain. These data make a persuasive case for
CSF1R-regulated microglial cells having an important role in the development of a
functional neuronal circuitry. Further evidence for the involvement of microglial cells comes
from in vitro studies of rat embryonic brains, in which CSF1 promotes process outgrowth
and neuronal survival in mixed cell cultures but not in pure neuronal cultures58.
The molecular basis of the functions of microglial cells in brain development remains to be
determined, but it is instructive that during brain injury, microglial cells are important in
orchestrating wound repair61. For example, implantation of macrophages greatly promoted
the regeneration of the spinal cord in paraplegic rats62, and in an ischaemia model, depletion
of microglial cells increased the area of the infarction whereas administration of CSF1
stimulated microglial-cell proliferation and decreased infarct size63. Furthermore, in
Csf1op/op mice, fewer microglial cells are recruited to the site of injury and neuronal survival
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is compromised compared with wild-type mice that have comparable injuries64. Microglial
cells also metabolize steroid hormones65, and this function might have a role in sexualizing
the brain during puberty. Microglial cells have also been shown to produce a wide range of
growth factors, including insulin-like growth factor 1 (IGF1), and various neurotrophic and
protective factors, such as nerve growth factor and neurotropin 3. It seems probable that
these factors are involved in the establishment of normal neuronal circuitry during
development.
Angiogenesis
Macrophages have been implicated in the regulation of angiogenesis during wound
healing66,67, but there has been little focus on their roles in angiogenesis during
development. Nevertheless, macrophage ablation using a suicide gene approach (that is, the
expression of a gene that induces apoptosis) has definitively shown the importance of
macrophages in vascular remodelling during eye development68. In this tissue, there are
three connected but anatomically distinct vascular structures that are remodelled post-natally
in mice (FIG. 5). In one of these, the hyaloid vessel system, macrophages are closely
associated with the blood vessels, and their ablation, either using a suicide gene approach or
through their loss in PU.1-deficient mice, results in a failure of remodelling and persistence
of the vascular structure post-natally68. The mechanism of this macrophage-mediated effect
is through their production of WNT7B, which stimulates adjacent vascular endothelial cells
to enter the S phase of the cell cycle and to subsequently undergo apoptosis as a result of the
lack of a survival signal from pericytes (mesenchymal cells that are associated with the
walls of small blood vessels)69,70. This not only allows for vascular remodelling to occur,
but also ensures that the macrophages are in place to phagocytose the resultant apoptotic
endothelial cells69,70. Importantly, in another developmental context, the ablation of
monocyte-derived DCs during embryo implantation in mice inhibited decidualization owing
to defective angiogenesis, and this resulted in the termination of pregnancy. In this study,
DCs seemed to regulate angiogenesis at the implantation site through the production of
vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGFβ1)71.
Further support for the role of macrophages in angiogenesis came from studies using
tetracycline-regulated expression of VEGF in the heart and lungs of normal mice, which
increased angiogenesis. VEGF recruited numerous bone-marrow-derived macrophages to
the tissue through signalling by CXC-chemokine receptor 4 (CXCR4), the ligand for which
is expressed by pericytes. These cells had all the characteristics of macrophages and secreted
angiogenic molecules as assayed by an aortic ring sprouting assay72. These data indicate that
VEGF not only causes endothelial-cell proliferation and permeability of vessels, but also
acts with other angiogenic factors that are derived from macrophages to form patent vessels.
A similar mechanism involving CXC-chemokine ligand 12 (CXCL12) signalling to CXCR4
has also been described, whereby CXCL12 was shown to guide these bone marrow
progenitor cells to sites of vascular expansion in the embryo73. In addition, CXCR4 and
CXCL12 were upregulated in response to hypoxia in ischaemic tissue, which resulted in the
recruitment of similar myeloid cells73.
Other trophic functions
Macrophages are also involved in adipogenesis. Overexpression of CSF1 in rabbit adipose
tissue increased the number of macrophages and fat mass, whereas administration of CSF1-
specific antibody had the opposite effect74,75. Furthermore, Csf1op/op mice are smaller in
size (as are tl rats)39,76 and have decreased fat mass, and this growth defect can be partially
reversed by the administration of CSF1 (REF. 43). Interestingly, these mice completely fail
to induce the formation of brown fat in the mammary gland during development because of
a defect in their neuroendocrine system77.
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Macrophages are also involved in the development and growth of myocytes. Specifically,
they secrete growth factors and suppress the apoptosis of myocytes through cell-to-cell
contact78,79. Furthermore, macrophages are recruited to the site of repair during muscle
regeneration through the autocrine production of urokinase plasminogen activator, and there
they stimulate the development of myocytes by producing IGF1 (REF. 80).
In addition, macrophages are crucial for erythrogenesis because they can identify ejected
nuclei and degrade them. Indeed, genetic ablation of the nuclease enzyme DNase II, which
is expressed by macrophages, resulted in peri-natal lethality owing to a macrophage failure
to envelop and degrade the ejected nuclei of erythrocytes81, resulting in the blockage of
erythrogenesis and lethal anaemia.
There are also many other deficiencies in Csf1op/op mice such as dermal atrophy that have
been noted but have not yet been studied in detail, although this might simply be a reflection
of the severe depletion of macrophages that normally constitute a large proportion of the
cells in the skin82.
There is also evidence of a role for macrophages in the development of other organisms. For
example, the ablation of macrophages in Xenopus laevis using a suicide gene approach
resulted in severe developmental abnormalities, including disruption of limb morphogenesis
and death at metamorphosis83.
These studies involving the in vivo depletion of macro phages or inhibition of CSF1-
regulated signalling in this population indicate that macrophages have an important role in
development in various species and tissues. These functional studies are also consistent with
deductions made from recent transcriptional profiling assays in macrophages of mice and
humans9,84. Below, I suggest that these developmental functions in matrix remodelling,
epithelial proliferation and outgrowth, angio genesis and tissue organization are subverted in
various pathological conditions.
Macrophages in disease
Macrophages are involved in almost every disease through their immunological and wound-
healing functions. In addition, I argue that in some cases, particularly in chronic diseases
such as cancer and obesity, the developmental activities of macrophages described above are
dysregulated and that these activities contribute to disease pathology.
Cancer
All solid tumours recruit macrophages into their microenvironment (known as tumour-
associated macrophages; TAMs). Originally it was thought that these cells were attempting
to reject the immunologically `foreign' cancer; indeed, macrophages can kill tumour cells in
vitro85. However, clinical and experimental evidence indicates that in most cases,
macrophages promote the progression and malignancy of tumours86–88. For example, the
density of TAMs in human tumours correlates with poor prognosis in more than 80% of
cases89. Overexpression of CSF1 and other macrophage chemoattractants, such as CXCl2,
correlates with poor prognosis in many types of cancer90–92. Experimental evidence in line
with these clinical correlations comes from genetic experiments in which macrophages were
removed from the polyoma middle T (PyMT) mouse model of breast cancer by crossing
these mice with mice carrying the Csf1op mutation; this resulted in a delay of tumour
progression and inhibition of metastasis93. This inhibition of malignancy could be reversed
by the restricted transgenic expression of CSF1 by mammary tissues in Csf1op/op mice,
which restored the macrophage population in the tumours93. Furthermore, overexpression of
CSF1 in wild-type tumours recruited macrophages prematurely, which accelerated tumour
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progression and increased the metastatic potential of the tumours93. Similarly, macrophage
ablation using Csf1op/op mice in a model of intestinal cancer that is caused by the APCΔ716
mutation suppressed tumour progression94. There are also several studies using tumour
xenografts in which macrophage depletion decreased tumour growth86,95,96. In addition,
antisense-RNA-mediated or antibody-mediated inhibition of either CSF1 or CSF1R in mice
inhibited macrophage recruitment to the tumour and decreased tumour growth in human
xenograft tumour models97,98. These data provide compelling evidence that tumours can
direct the behaviour of macrophages from a potentially hostile antitumour phenotype to one
that promotes malignancy. So, what is the precise nature and function of these tumour-
promoting macrophages87?
As they become malignant, tumours acquire increased vasculature in a process known as the
angiogenic switch99. This vasculature provides the sustenance and oxygen that is required
for tumours to grow rapidly100. Macrophage ablation in the PyMT model of breast cancer
inhibited this angiogenic switch and also decreased the density of the vasculature in
malignant tumours. By contrast, the premature recruitment of macrophages into hyperplastic
lesions through over-expression of CSF1 caused an angiogenic switch even in these non-
malignant tumours101. Macrophages express many angiogenic molecules, including VEGF,
in breast tumours of humans and mice102,103. This temporal and spatial presentation of
VEGF is at least part of the tumour-promoting function of macrophages, as overexpression
of VEGF in a regulated way in adenomas of Csf1op/op mice expressing the PyMT oncogene
in the mammary epithelium caused extensive vascularization and accelerated tumour
progression to malignancy to wild-type rates104. Furthermore, the depletion of macrophages
through the inhibition of CSF1 or CSF1R in xenograft models, as described above,
decreased angiogenesis, and this coincided with a decrease in the levels of VEGF97,98.
Consistent with these observations, depletion of VEGF specifically in myeloid cells blocks
the angiogenic switch. Paradoxically, this enhances tumour growth because the vessels have
better flow characteristics in the absence of VEGF105. These data indicate that there is a
complex interaction between many macrophage functions and the transition to carcinoma.
A subpopulation of mononuclear phagocytes has also been shown to be particularly
angiogenic in ex vivo assays and in xenograft tumour assays. These cells express the
endothelial-cell marker TIE2 receptor (also known as TEK) and are known as TIE2-
expressing monocytes (TEMs). Their importance is shown by their ablation using a suicide
gene approach, which blocks angiogenesis in xenografted tumours106.
Furthermore, macrophages are attracted to hypoxic areas of advanced tumours, and many
chemoattractive signals have been identified92. At these sites, the hypoxia-induced
transcription factor HIFα (hypoxia inducible factor α-subunit) is upregulated in
macrophages, and this activates several genes, including angiogenic factors such as
VEGF92. The activation of these angiogenic factors results in the revascularization of the
hypoxic areas and the survival of the tumour cells that reside within them, thereby further
contributing to malignancy92.
Intravital imaging of fluorescently labelled cells in mammary tumours has shown that, in
most cases, tumour-cell motility occurs next to macrophages107,108. Moreover, intravasation
of tumour cells also occurs next to clusters of macrophages on the vessel surface in vivo107.
This concordant movement of macrophages and tumour cells depends on both cell types and
requires epidermal growth factor (EGF) and CSF1 cross-signalling108, as inhibition of either
pathway blocks the movement of both cell types and decreases the number of circulating
cells that are derived from the tumour108. Further evidence for macrophage–tumour-cell
crosstalk comes from co-culture experiments of MCF-7 breast cancer cells and
macrophages, which result in enhanced invasiveness of the MCF-7 cells. This was caused by
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macrophage expression of WNT5A or tumour necrosis factor (TNF), which upregulated the
expression of metalloproteases, the actions of which are required to remodel the
extracellular matrix to facilitate tumour-cell migration109,110. In addition, by producing
TNF, macrophages promote intestinal cancer, as TNF activates the WNT–β-catenin
pathway, which is known to be essential for tumour progression in intestinal cells94.
In summary, macrophages promote malignancy by enhancing epithelial tumour-cell
invasion and migration through the stroma and into the blood vessels and by stimulating
angiogenesis, thereby increasing the number of targets for intravasating cells and supplying
oxygen and nutrients. Consistent with these developmental functions, the TAM
transcriptome is enriched in a set of mRNA transcripts, including angiogenic mediators,
metalloproteases and growth factors, that also define embryonic macrophages111. By
contrast, the expression of immune-activating transcripts is decreased, and this coincides
with the upregulation of immunosuppressive transcripts112. These data suggest that the
tumour environment is educating macrophages to carry out trophic functions and to adopt an
M2-like macrophage phenotype (see above). In fact, macrophages that develop in the
presence of growth factors such as CSF1 (REF. 21) or in response to molecules that signal
through nuclear factor-κB (NF-κB)113,114 are non-immunogenic and trophic, which is
consistent with a role for the cytokine environment in modulating macrophage development.
It is important to point out that macrophages that are found in progressing tumours are
different from those that are involved in chronic inflammatory responses to pathogens or
irritants, which seem to be responsible for cancer initiation because they create a mutagenic
and growth-promoting environment115,116. Instead, I think that the macrophages that are
recruited to progressing tumours are functionally similar to those found in developing
tissues117.
Rheumatoid arthritis
Many autoimmune diseases, including rheumatoid arthritis, involve inflammatory responses
to autoantibodies that activate Fc receptors to trigger mast-cell and macrophage activation,
and neutrophil invasion. This leads to an intense local inflammatory response and, if not
resolved, to tissue damage over time with cycles of repair and destruction. In rheumatoid
arthritis, CSF1 is produced constitutively by synovial fibroblasts and recruits tissue-
infiltrating monocytes and macrophages21. In addition, locally produced CSF1, together
with RANKl, induces the differentiation of monocytes to osteoclasts, which trigger bone
loss40. Csf1op/op mice are resistant to collagen-induced arthritis, and CSF1 administration in
wild-type mice exacerbated arthritis if administered after collagen treatment118. CSF1 also
increased the severity of arthritis in a methylated albumin knee joint model that involved
macrophage recruitment, and macrophage ablation inhibited disease progression21. These
data show that macrophages are central to the pathogenesis of rheumatoid arthritis. Although
the immune functions of macrophages are intricately involved in the initiation and
propagation of this disease, it is also evident that the uncontrolled trophic and tissue-
remodelling roles of macrophages are essential for much of the disease pathology. This
includes the laying down of extracellular matrix, the formation of collagen fibrils and
angiogenesis: macrophage functions that are similar to those seen during development21. In
addition, much of the bone loss in rheumatoid arthritis can be ascribed to inappropriate and
unrestrained osteoclastic function.
Lipid metabolism
Macrophages express various receptors for modified forms of lipid and they are one of the
main scavengers for low-density lipoprotein. Indeed, during atherosclerosis, the continuous
uptake of oxidized lipoproteins generates fat-laden macrophages in the arterial walls, which
are known as foam cells21. These cells interact with endothelial cells, pericytes and platelets
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to form thrombi that eventually result in vascular occlusion. It is also appreciated that the
build-up of lipid-filled thrombotic plaques in the arteries is a modified form of
inflammation, in which monocyte-derived macrophages have a central role. Ablation of
macrophages in a mouse model of atherosclerosis that is caused by a homozygous null
mutation in the gene that encodes apolipoprotein E through crossing with Csf1op/op mice
decreased the development of plaques, indicating the central role of macrophages in this
process119. By contrast, treatment of hyperlipidaemic rabbits with CSF1 decreased
atherosclerosis120. These observations suggest that macrophages have important roles in
atherosclerotic disease, both during instigation and resolution.
Although these functions are clearly related to the scavenging roles of macrophages, they
also indicate that macrophages have a normal physiological role in lipid metabolism. In this
context an interesting story is evolving around the role of macrophages in adipogenesis and
obesity. Macrophages are found in adipose tissue and are increased in obese mice and
humans121. Here, they modulate angiogenesis for remodelling of the adipose tissue122. As
mentioned above, the recruitment of macrophages to adipose tissue increases fat mass74,
suggesting that these cells have an important developmental role in the regulation of
obesity121,123. The production of monomeric tartrate-resistant acid phosphatase by
macrophages stimulates fat-cell production and hyperplastic obesity (which involves the
generation of many small fat cells) in a transgenic mouse model124. It is also evident that
obesity causes a low-level inflammatory state that is in part responsible for insulin
resistance123. Macrophages can account for this heightened inflammatory state121, as
macrophage ablation reversed inflammation and insulin resistance in this model125.
Therefore, overactivity of the normal developmental roles of macrophages seems to be, at
least in part, responsible for the two important diseases of lipid metabolism, obesity and
atherosclerosis.
Conclusions
Macrophages have important roles in the development of many and perhaps all tissues, as
well as in their ongoing homeostasis. This is not an instructive role; macrophages do not
change cell identity, but instead affect the regulation of rates of outgrowth, remodelling and
organization of tissues. In this respect, these motile cells are well suited to this role, as they
can be recruited as needed and disposed of at completion. I think that these are ancient roles
of these primitive cells found in almost all metazoans and that as the immune system
evolved, new functions were overlaid on these developmental and homeostatic functions,
thereby exploiting the migratory, sensory and degradative properties of macrophages. This
gradually led to the evolution of further subclasses, such as DCs. unfortunately, the trophic
functions of these cells are dysregulated in many chronic diseases, some of which are
associated with ageing, and their unrestrained activities can exacerbate pathology. Thus, a
full appreciation of the developmental and tissue-maintenance roles of macrophages using
methods such as temporal ablation of subpopulations of cells or macrophage-specific gene
expression, will not only lead to deeper insights into macrophage biology but also allow the
development of more precisely targeted anti-macrophage therapies. Some of these are in fact
already being tested in clinical trials, for example, for the treatment of rheumatoid
arthritis21.
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Reticuloendothelial system
A classification system, the functional definition of which is based on phagocytosis, that
groups macrophages and endothelial cells together.
Mononuclear phagocytic system
The current classification of macrophages, which is an ontological classification based on
their bone marrow and monocyte origin.
Definitive haematopoiesis
Haematopoiesis that results in the generation of all blood cell types.
Osteopetrosis
A disease that is associated with the failure to remodel bone, resulting in occluded
marrow cavities — literally, `rock-like' bones.
Growth plate
The area where osteoblasts initiate bone deposition and osteoclasts trigger bone
remodelling.
Liposome-encapsulated clodronate
Clodronate (dichloromethylene bisphosphonate) that is encapsulated in liposomes and
that is taken up preferentially by macrophages through phagocytosis. The clodronate then
kills the macrophages.
Hypothalamic–pituitary–gonadal axis
The feedback system that regulates reproduction through the synthesis of sex steroid
hormones in males and females. The highest level of control is in the hypothalamus, a
region of the brain that secretes gonadotrophin-releasing hormone, which in turn
stimulates the pituitary to produce gonadotrophins that act on the gonads to stimulate sex
hormone synthesis.
Visual evoked potential
A neuronal response to repeated visual cues.
Retinal striate conductance
The pathway of neuronal impulses from the retina up the optic nerve to the striatum in
the brain. The timing of this is a measure of neuronal conductance from a peripheral
organ to the brain.
Hyaloid vessel system
A vessel system that is laid down during the development of the eye and needs to be
remodelled to allow unobstructed vision.
Decidualization
The process of stromal transformation in response to an invading embryo in the uterus.
The transformed stroma protects and provides sustenance to the embryo and converts into
a portion of the placenta as embryonic development proceeds.
Aortic ring sprouting assay
An angiogenic assay that depends on vascular sprouting from small rings of aorta
cultured ex vivo.
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Brown fat
A type of fat involved in thermogenesis, so called because of the large number of
mitochondria that give it its brown colour.
Polyoma middle T (PyMT) mouse model
A transgenic mouse model of breast cancer. The cancer is caused by the restricted
expression of the polyoma middle T oncoprotein by mammary epithelial cells, which is
under the control of the mouse mammary tumour virus promoter. This model is highly
metastatic and recapitulates much of what is seen in human cancers.
Angiogenic switch
The marked increase in vascularization that is observed as benign tumours transition to
malignancy.
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Figure 1. The mononuclear phagocytic lineage and the control of its development by growth
factors
Cells of the mononuclear phagocytic system (MPS) arise in the bone marrow, where they
develop from pluripotent stem cells (PPSCs) through various multipotent progenitor stages:
granulocyte/macrophage colony-forming unit (GM-CFU) to macrophage CFU (M-CFU) to
monoblast to pro-monocyte. In the bone, osteoclast progenitors develop from these cells
under the influence of colony-stimulating factor 1 (CSF1), and these differentiate in
response to receptor activator of nuclear factor-κB ligand (RANKL) into osteoclasts.
Another population differentiates into bone marrow macrophages also in response to CSF1,
and the ex vivo culture of these cells and their progenitors is often used for macrophage
studies. In addition, monocytes are released into the circulation. There is a growing body of
evidence for an as yet undefined number of subpopulations of monocytes126 that have
different developmental fates defined by the markers shown. LY6Chi monocytes consist of
at least two types according to their expression of CXC-chemokine receptor 2 (CXCR2) and
differentiate into dendritic cells of different types according to the state of inflammation and
cytokine and/or growth factor exposure. Other as yet undefined types of monocytes are
LY6Clow and differentiate into tissue-resident macrophages in response to CSF1; these have
different names and functions according to their tissue residency (TABLE 1). Alternatively
activated macrophages differentiate in response to parasitic infection, allergic conditions and
during tissue repair through the effects of interleukin-13 (IL-13) and IL-4; these are also
known as M2 macrophages. Inflammatory macrophages (also known as M1 macrophages)
can also be found at sites of infection and injury, and these develop under the influence of
GM-CSF, interferon-γ (IFNγ) and tumour necrosis factor (TNF). Immature macrophages
can also differentiate into dendritic cells (not shown). In addition, TIE2-expressing
monocytes (TEMs) give rise to TIE2+ macrophages that are involved in angiogenesis in
tumours. It should also be noted that in addition to the growth factors shown here, many
other ligands, particularly those that signal through Toll-like receptors, influence
macrophage differentiation. In addition, the rigid lineage diagrams and growth factor
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assignments depicted here are for illustrative purposes only. In fact, there can be cross-
differentiation of macrophage phenotypes during the evolution of an immune response, and
tissue-restricted progenitors can expand within a tissue through proliferation. In addition,
growth factors can act differently according to context and desired response, for example
CSF1 receptor signalling is required for Langerhans-cell differentiation but CSF1 can act
with IL-4 to inhibit dendritic-cell differentiation, at least in vitro. These complexities cannot
be represented in such a simple lineage diagram but they are discussed in REFs 18,22,126.
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Figure 2. The trophic role of macrophages in bone morphogenesis
Colony-stimulating factor 1 (CSF1) is required for the formation of a common monocyte–
osteoclast progenitor cell in the bone marrow that then proliferates and differentiates in the
presence of receptor activator of nuclear factor-κB ligand (RANKL) to form multinuclear
osteoclasts. These remodel the bone that is laid down by osteoblasts. To coordinate these
processes, osteoblasts produce CSF1, which not only mediates the correct positioning of
osteoclasts but also affects their local function.
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Figure 3. The trophic role of macrophages in ductal branching
In the mammary gland, macrophages are found in the stroma immediately adjacent to the
growing terminal end bud (TEB) and are often associated with collagen fibres, which they
help to form. Ablation of macrophages slows outgrowth and branching of the TEB into the
fatty stroma, and this is associated with a disruption of collagen fibrillogenesis.
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Figure 4. The trophic role of macrophages in neuronal patterning
Microglial cells are a specialized type of macrophage found in the brain. These cells respond
to colony-stimulating factor 1 receptor (CSF1R) signalling to produce factors that are
required for the establishment of neuronal connectivity. Depletion of CSF1 shows that,
among other things, microglial cells regulate the hypothalamic–pituitary–gonadal axis
through negative signalling from neurons that respond to γ-aminobutyric acid A (GABAA
neurons; known as GABAnergic) and positive signalling from excitatory neurons, which
allows gonadotrophin-releasing hormone (GnRH) to be released in a pulsatile manner into
the median eminence. This induces the release of luteinizing hormone by the pituitary,
which controls testosterone and oestrogen biosynthesis in the gonads. IGF1, insulin-like
growth factor 1; IL-34, interleukin-34; NGF, nerve growth factor.
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Figure 5. The trophic role of macrophages in angiogenesis and vascular remodelling
During eye development, the hyaloid vessel system regresses and is re-patterned.
Macrophages closely associated with the vessels synthesize WNT7B, which stimulates
vascular endothelial cells to enter the DNA synthesis phase of the cell cycle. In the presence
of pericyte-produced angiopoietin 2 (ANG2), the survival signal from ANG1 is blocked and
the endothelial cells undergo apoptosis and are phagocytosed by the macrophages. In this
manner, vascular regression and proper patterning is achieved69,70.
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Table 1
Diversity of macrophages
Tissue Specific macrophage name Function
Bone Osteoclast Bone remodelling and providing a stem cell niche
Bone marrow macrophage Erythropoiesis
Brain Microglial cell Neuronal survival and connectivity, and repair after injury
Epidermis Langerhans cell Immune surveillance
Eye NA Vascular remodelling
Intestine Crypt macrophage Immune surveillance
Kidney NA Ductal development
Liver Kupffer cell Clearance of debris from blood and liver tissue regeneration after damage; liver
development?
Mammary gland NA Branching morphogenesis and ductal development
Ovary NA Steroid hormone production and ovulation
Pancreas NA Islet development
Testis NA Steroid hormone production; Leydig-cell development?
Uterus Uterine DC Angiogenesis and decidualization
Uterine macrophage Cervical ripening
DC, dendritic cell; NA, not applicable.
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